XML 59 R39.htm IDEA: XBRL DOCUMENT
v3.24.0.1

COMMERCIALIZATION AGREEMENTS (Details) - USD ($) $ in Thousands |  | 1 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | ---
Mar. 29, 2021 | Jul. 23, 2018 | Oct. 19, 2017 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | May 13, 2021 | Oct. 31, 2015
Payment for promissory note |  |  |  | $ 0 | $ 0 | $ 4,086 |  |
Pfizer |  |  |  |  |  |  |  |
Promissory note |  |  |  |  |  |  |  | $ 4,300
Payment for promissory note | $ 4,000 |  |  |  |  |  |  |
Chiesi Agreements |  |  |  |  |  |  |  |
Non-refundable payment receivable |  | $ 25,000 | $ 25,000 | 50,000 |  |  |  |
Payments in consideration for development services performed |  |  |  | 45,000 |  |  |  |
Payments in connection with performance of additional studies |  |  |  | 51,300 |  |  |  |
Agreement amendment payment receivable |  |  |  | 30,000 |  |  |  |
Chiesi US Agreement |  |  |  |  |  |  |  |
Additional amounts payable to cover development costs |  | 20,000 |  |  |  |  |  |
Maximum entitlement of development costs to cover per year |  | 7,500 |  |  |  |  |  |
Additional amount payable for achievement of regulatory and commercial milestones |  | $ 760,000 |  | $ 735,000 |  |  |  |
Chiesi US Agreement | Maximum |  |  |  |  |  |  |  |
Payment on net sales percentage |  | 40.00% |  | 40.00% |  |  |  |
Chiesi US Agreement | Minimum |  |  |  |  |  |  |  |
Payment on net sales percentage |  | 15.00% |  | 15.00% |  |  |  |
Chiesi Ex-US Agreement |  |  |  |  |  |  |  |
Additional amounts payable to cover development costs |  |  | 25,000 |  |  |  |  |
Maximum entitlement of development costs to cover per year |  |  | 10,000 |  |  |  |  |
Additional amount payable for achievement of regulatory and commercial milestones |  |  | $ 320,000 |  |  |  |  |
Agreement amendment payment receivable |  |  |  |  |  |  | $ 10,000 |
Chiesi Ex-US Agreement | Maximum |  |  |  |  |  |  |  |
Payment on net sales percentage |  |  | 35.00% | 35.00% |  |  |  |
Chiesi Ex-US Agreement | Minimum |  |  |  |  |  |  |  |
Payment on net sales percentage |  |  | 15.00% | 15.00% |  |  |  |

X
- Definition The total amount payable to entity for the achievement of regulatory and commercial milestones. + References No definition available. + Details
Name: | plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount payable to the entity to cover development costs under agreement. + References No definition available. + Details
Name: | plx_AdditionalAmountsPayableToCoverDevelopmentCosts
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Agreement Amendment Payment Receivable + References No definition available. + Details
Name: | plx_AgreementAmendmentPaymentReceivable
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount payable to entity to cover development costs in any year under agreement. + References No definition available. + Details
Name: | plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash inflow from consideration received for development services performed. + References No definition available. + Details
Name: | plx_PaymentInConsiderationForDevelopmentServicesPerformed
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the payment as a percentage of future net sales. + References No definition available. + Details
Name: | plx_PaymentOnNetSalesPercentage
Namespace Prefix: | plx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow in connection with performance of additional studies. + References No definition available. + Details
Name: | plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights. + References No definition available. + Details
Name: | plx_UpfrontNonrefundableNoncreditablePaymentReceivable
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_NotesPayableCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflow for a borrowing supported by a written promise to pay an obligation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details
Name: | us-gaap_RepaymentsOfNotesPayable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |